These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 28212557)

  • 21. Early reappearance of intraclonal proliferative subpopulations in ibrutinib-resistant chronic lymphocytic leukemia.
    Pozzo F; Forestieri G; Vit F; Ianna G; Tissino E; Bittolo T; Papotti R; Gaglio A; Terzi di Bergamo L; Steffan A; Polesel J; Bulian P; Laureana R; Tafuri A; Chiarenza A; Di Raimondo F; Olivieri J; Zaja F; Laurenti L; Del Principe MI; Postorino M; Del Poeta G; Bomben R; Zucchetto A; Rossi D; Gattei V
    Leukemia; 2024 Aug; 38(8):1712-1721. PubMed ID: 38914716
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Phospholipase Cγ2 Mutants R665W and L845F Identified in Ibrutinib-resistant Chronic Lymphocytic Leukemia Patients Are Hypersensitive to the Rho GTPase Rac2 Protein.
    Walliser C; Hermkes E; Schade A; Wiese S; Deinzer J; Zapatka M; Désiré L; Mertens D; Stilgenbauer S; Gierschik P
    J Biol Chem; 2016 Oct; 291(42):22136-22148. PubMed ID: 27542411
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dissection of subclonal evolution by temporal mutation profiling in chronic lymphocytic leukemia patients treated with ibrutinib.
    Gángó A; Alpár D; Galik B; Marosvári D; Kiss R; Fésüs V; Aczél D; Eyüpoglu E; Nagy N; Nagy Á; Krizsán S; Reiniger L; Farkas P; Kozma A; Ádám E; Tasnády S; Réti M; Matolcsy A; Gyenesei A; Mátrai Z; Bödör C
    Int J Cancer; 2020 Jan; 146(1):85-93. PubMed ID: 31180577
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BTK Inhibitors in Chronic Lymphocytic Leukemia.
    Gaballa S; Pinilla-Ibarz J
    Curr Hematol Malig Rep; 2021 Oct; 16(5):422-432. PubMed ID: 34599723
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib.
    Bonfiglio S; Sutton LA; Ljungström V; Capasso A; Pandzic T; Weström S; Foroughi-Asl H; Skaftason A; Gellerbring A; Lyander A; Gandini F; Gaidano G; Trentin L; Bonello L; Reda G; Bödör C; Stavroyianni N; Tam CS; Marasca R; Forconi F; Panayiotidis P; Ringshausen I; Jaksic O; Frustaci AM; Iyengar S; Coscia M; Mulligan SP; Ysebaert L; Strugov V; Pavlovsky C; Walewska R; Österborg A; Cortese D; Ranghetti P; Baliakas P; Stamatopoulos K; Scarfò L; Rosenquist R; Ghia P
    Blood Adv; 2023 Jun; 7(12):2794-2806. PubMed ID: 36696464
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation.
    Reiff SD; Mantel R; Smith LL; Greene JT; Muhowski EM; Fabian CA; Goettl VM; Tran M; Harrington BK; Rogers KA; Awan FT; Maddocks K; Andritsos L; Lehman AM; Sampath D; Lapalombella R; Eathiraj S; Abbadessa G; Schwartz B; Johnson AJ; Byrd JC; Woyach JA
    Cancer Discov; 2018 Oct; 8(10):1300-1315. PubMed ID: 30093506
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non-Hodgkin lymphoma.
    Zhang SQ; Smith SM; Zhang SY; Lynn Wang Y
    Br J Haematol; 2015 Aug; 170(4):445-56. PubMed ID: 25858358
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Resistance Mutations to BTK Inhibitors Originate From the NF-κB but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway.
    Smith CIE; Burger JA
    Front Immunol; 2021; 12():689472. PubMed ID: 34177947
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors.
    Cheng S; Guo A; Lu P; Ma J; Coleman M; Wang YL
    Leukemia; 2015 Apr; 29(4):895-900. PubMed ID: 25189416
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK/PLCG2 mutations.
    Lucas F; Larkin K; Gregory CT; Orwick S; Doong TJ; Lozanski A; Lozanski G; Misra S; Ngankeu A; Ozer HG; Sampath D; Thangavadivel S; Yilmaz SA; Rogers KA; Byrd JC; Woyach JA; Blachly JS
    Blood; 2020 Jun; 135(24):2192-2195. PubMed ID: 32232486
    [No Abstract]   [Full Text] [Related]  

  • 31. Kinase-deficient BTK mutants confer ibrutinib resistance through activation of the kinase HCK.
    Dhami K; Chakraborty A; Gururaja TL; Cheung LW; Sun C; DeAnda F; Huang X
    Sci Signal; 2022 May; 15(736):eabg5216. PubMed ID: 35639855
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition.
    Burger JA; Landau DA; Taylor-Weiner A; Bozic I; Zhang H; Sarosiek K; Wang L; Stewart C; Fan J; Hoellenriegel J; Sivina M; Dubuc AM; Fraser C; Han Y; Li S; Livak KJ; Zou L; Wan Y; Konoplev S; Sougnez C; Brown JR; Abruzzo LV; Carter SL; Keating MJ; Davids MS; Wierda WG; Cibulskis K; Zenz T; Werner L; Dal Cin P; Kharchencko P; Neuberg D; Kantarjian H; Lander E; Gabriel S; O'Brien S; Letai A; Weitz DA; Nowak MA; Getz G; Wu CJ
    Nat Commun; 2016 May; 7():11589. PubMed ID: 27199251
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib.
    Guo A; Lu P; Galanina N; Nabhan C; Smith SM; Coleman M; Wang YL
    Oncotarget; 2016 Jan; 7(4):4598-610. PubMed ID: 26717038
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development and characterization of prototypes for in vitro and in vivo mouse models of ibrutinib-resistant CLL.
    Aslan B; Kismali G; Chen LS; Iles LR; Mahendra M; Peoples M; Gagea M; Fowlkes NW; Zheng X; Wang J; Vellano CP; Marszalek JR; Bertilaccio MTS; Gandhi V
    Blood Adv; 2021 Aug; 5(16):3134-3146. PubMed ID: 34424317
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors.
    Wang E; Mi X; Thompson MC; Montoya S; Notti RQ; Afaghani J; Durham BH; Penson A; Witkowski MT; Lu SX; Bourcier J; Hogg SJ; Erickson C; Cui D; Cho H; Singer M; Totiger TM; Chaudhry S; Geyer M; Alencar A; Linley AJ; Palomba ML; Coombs CC; Park JH; Zelenetz A; Roeker L; Rosendahl M; Tsai DE; Ebata K; Brandhuber B; Hyman DM; Aifantis I; Mato A; Taylor J; Abdel-Wahab O
    N Engl J Med; 2022 Feb; 386(8):735-743. PubMed ID: 35196427
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance.
    Naeem A; Utro F; Wang Q; Cha J; Vihinen M; Martindale S; Zhou Y; Ren Y; Tyekucheva S; Kim AS; Fernandes SM; Saksena G; Rhrissorrakrai K; Levovitz C; Danysh BP; Slowik K; Jacobs RA; Davids MS; Lederer JA; Zain R; Smith CIE; Leshchiner I; Parida L; Getz G; Brown JR
    Blood Adv; 2023 May; 7(9):1929-1943. PubMed ID: 36287227
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BTK-independent regulation of calcium signalling downstream of the B-cell receptor in malignant B-cells.
    Arthur R; Wathen A; Lemm EA; Stevenson FK; Forconi F; Linley AJ; Steele AJ; Packham G; Valle-Argos B
    Cell Signal; 2022 Aug; 96():110358. PubMed ID: 35597428
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia.
    Deng J; Isik E; Fernandes SM; Brown JR; Letai A; Davids MS
    Leukemia; 2017 Oct; 31(10):2075-2084. PubMed ID: 28111464
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia.
    Xu L; Tsakmaklis N; Yang G; Chen JG; Liu X; Demos M; Kofides A; Patterson CJ; Meid K; Gustine J; Dubeau T; Palomba ML; Advani R; Castillo JJ; Furman RR; Hunter ZR; Treon SP
    Blood; 2017 May; 129(18):2519-2525. PubMed ID: 28235842
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Second-generation inhibitors of Bruton tyrosine kinase.
    Wu J; Liu C; Tsui ST; Liu D
    J Hematol Oncol; 2016 Sep; 9(1):80. PubMed ID: 27590878
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.